drugset / Trial / NCT03116971
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Phase 1
Terminated
2 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose of the study was to assess the Safety and Efficacy of M3814 in combination with chemotherapy with SCLC ED.
Timeline
- Start
- 2017-05-25
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment in the study was prematurely terminated due to recruitment challenges and not due to concerns of safety for the participants.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NEDISERTIB | Small molecule | 100 mg | Oral |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |